02. December 2016.
The regional pharmaceutical industry leader, Hemofarm, closes this year with good news. In addition to a record-breaking output, several tens of millions euro worth investments and huge confidence of the consumers in more than 38 countries on three continents, this year Hemofarm also rounds up the tenth year of operations within the international STADA Group. A ceremonial cocktail party thrown for friends, partners and associates was a good occasion to sum up the business year results of this pharmaceutical giant. In the very finish of the year, Hemofarm marked two important events: becoming a hub of STADA Group for Southeast Europe and opening of a new Quality building which is the focal point encompassing cutting-edge equipment and highly educated staff.
‘This is not only a confirmation of continuing investments by STADA in the business in Serbia, it is rather a huge argument that generic industry is not a mere copier but also an innovator in production of available, safe and top-quality products which are intended exclusively for the sake of the nation’s health. It is not possible to achieve the substantial success without building genuine, professional, trustful relations not only with patients, but also with doctors, wholesalers and representatives of institutions. That’s why Hemofarm is the strongest one, because it believes in such relations, it strives to cherish them carefully and gives its best to improve them further’, Dr Ronald Seeliger, CEO of Hemofarm and Vice President of STADA Group for Southeast Europe, said.
This year, for the first time since the establishment of its operations in Bosnia and Herzegovina, Hemofarm in Banjaluka has become the market leader in this country. The plan is to boost the operations also in the strategic regional markets in Montenegro, Albania and Macedonia.
